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Abstract
The percentage of young adults who had mental illnesses has increased from 2008 to 2015.
However, few existing studies investigating the potential
benefits of multivitamin-mineral (MVM) supplementation on mental health focused on young
adults (18-24 years of age), whose eating behaviors are often unhealthy. The purpose of this
study was to examine the effects of a MVM supplement on mental health in young
adults. One hundred and thirty-three college students (Mage=20.59, SD=1.77; 80.15% female)
participated in this randomized, double-blind, placebo-controlled trial. Participants consumed
either a MVM supplement or a placebo for 30 days. The supplement contained B Vitamins,
Vitamin C, calcium, magnesium, and zinc. Beck Anxiety Inventory (BAI), Center for
Epidemiologic Studies Depression Scale (CES-D), Abbreviated Dysregulation Inventory (ADI)
and a single item for self-esteem (SISE) were used to assess participants’ symptoms of
anxiety, depression, impulsivity/dysregulation, and self-esteem level at baseline and
on day 30. ADI explored three aspects of dysregulation (behavioral, cognitive, and affective).
Participants’ height and weight were recorded using standardized protocols by trained
staff. Data were analyzed using repeated measures ANCOVA. There was a difference in
adjusted mean score changes in depression within MVM supplementation or within
placebo-controlled group from baseline to Day 30 (p= 0.03). There was also a difference in
adjusted mean score changes in depression in MVM supplementation group compared to
placebo-controlled group (p= 0.02). In overweight/obese BMI group, no difference in adjusted
mean scores of anxiety, depression, dysregulation, or self-esteem level was found. However,
closer examination based on effect sizes revealed moderate effects of MVM supplementation

within-subjects on anxiety (η2= 0.11) and behavioral dysregulation (η2= 0.03) and
between-subjects on self-esteem level (η2= 0.03); within-subjects on anxiety (η2= 0.07),
depression (η2= 0.07), and cognitive dysregulation (η2= 0.07) and between-subjects on
depression (η2= 0.07) and self-esteem level (η2= 0.04) in overweight/obese BMI group. The
30-day MVM supplementation may have beneficial effects on young adults’ symptoms of
depression. Although outcomes presented no significant difference between pre-intervention
and post-intervention scores, some of them indicated relatively moderate effect sizes, and
future work should replicate with larger samples.
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Chapter 1
1

Introduction
Mental health is an increasing risk for people in the United States. In 2015, about 43.4

million American adults who were 18 years old or older (17.9%) had a mental illness in the
past year. 1 The percentage of adults with mental illnesses had been relatively stable since
2008; however, it increased from 2008 to 2015 among young adults (18-24 years old). 1 It has
been suggested that nutritional status may have a role in some mental health-related
conditions. Also, young adults aged 18-24 years are at a unique developmental stage as they
transition out of their parents’ home and are still shaping their identity and health behaviors.
At this stage, young adults are likely to be sensitive to their body weight and shapes. 2
Therefore, weight status may influence their mental health as well.
The remainder of this introduction section will state the importance of our study in
young adults. After that, some of these more common mental health status (namely anxiety
disorder, depression, and impulsivity/dysregulation) and self-esteem will be defined.
Moreover, the major risk factors of these psychological impairments will be discussed.
Furthermore, existing studies of multivitamin-mineral (MVM) use and psychological health
among adults, as well as the strengths and limitations of the studies will be addressed. Finally,
recommendations for future studies will be suggested.
1.1 Young Adults are at a Unique Developmental Stage
Young adults aged 18-24 years are at a unique developmental stage in the theory of
Arnett. 3 In this period, young adults aged 18-24 years have demographic diversity,
unpredictability of future. As they transition out of their parents’ home, they are open to
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various possibilities, taking partial responsibility of independent living, but still leaving other
responsibility to their parents, college authorities, or other adults. Eighteen to twenty-four year
olds are also distinct since they explore new behaviors, beliefs, and thoughts that will help
them shape themselves into the person that they want to become. Due to changes in their
residential status, school attendance, work status, and romance relationship, they may see
themselves as neither adolescents nor adults, but somehow in between. They pursue
self-sufficiency and are in transition to adults who accept their own responsibility, make
independent decisions, and become financially independent. Young adults in the age of
18-24 years are both biologically and socially different from adolescents aged 10-18 years or
adults aged over 24 year. They are different from adolescents who take few responsibilities in
the society or adults who take more responsibilities and have normative behaviors.
Additionally, young adults are more likely to be exposed to dangerous behaviors and have
worse health conditions in multiple areas. 2, 3 The suicide death rate among young adults
aged 20-24 years was 13.6 per 100,000 people, while among adolescents aged 15-19 years
was 7.5 per 100,000 people. Therefore, young adults have a higher rate of depression and
suicide. 2 In this case, young adulthood in the age of 18-24 years is a distinct period of time to
shape their life-long healthy eating behaviors and to prevent them from potential mental
health disorders. Therefore, we need to focus on these individuals.
1.2 Psychosocial Health
1.2.1 Anxiety Symptoms
When people are faced with a final exam, a job interview, or a meeting with their boss,
they might temporarily feel panic. However, the feeling with an anxiety disorder can last for
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days, months, or even years and can be hard to eliminate. 4 The symptoms of anxiety, worry,
panic, fear, or embarrassment interrupt people’s study, work, or ability to communicate with
other people. People with anxiety symptoms may have difficulty keeping a healthy social
relationship due to the antisocial behaviors caused by the chronic feelings. 4
From 2001 to 2003, approximately 19.1% of American adults aged 18 years and older
experienced anxiety disorders; among these, an estimated 22.3% of adults aged 18-29 years
had anxiety disorder. 5 Compared to males, the prevalence of anxiety disorder in females is
higher in American adults. 5
1.2.2 Depression
Depression is often comorbid with anxiety. 6 The symptoms of depression include sad
and anxious mood; hopelessness, guilt, worthlessness, or helplessness; and irritability.

7

People with depressive symptoms also show less or no interest in hobbies and activities and
may be non-energetic or restless. The symptoms may influence their work and life due to
issues with concentrating, remembering, and sleeping; change in appetite and/or weight;
thoughts or attempts of death or suicide; and physical pain with unknown reasons. Notably, it
is the most common mental illness among college students in the United States. 6 In 2016,
about 16.2 million (6.7%) adults suffered major depressive episodes; among these, 10.9% of
the adults aged 18-25 years underwent major depressive episodes. 8 Interestingly, the
prevalence in females is also higher for American adults compared to males, 8 which is
similar to the prevalence of anxiety disorder. This may be due to a personality difference or
some men’s unwillingness to show vulnerability and seek help, resulting in under-diagnosis.
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1.2.3 Impulsivity/Dysregulation
Impulsivity and dysregulation also often come with anxiety disorder and depression
among adolescents. 7 However, the mechanism and nature of the impairments still require
further clarification. Chamorro et al. 9 investigated the impulsivity rate in more than 30
thousand adults in the United States, and they found that 17% of the sample had impulsivity
impairment, indicating that impulsivity was prevalent, especially in men and younger people;
also, the impulsivity rate among participants aged 18-29 years was 21.67% (data for only
18-24 year olds not reported). Although there are several definitions of impulsivity, major
factors that contribute to impulsivity are motor (engaging in actions without enough thinking),
inattention, and non-planning. 10 Moreover, brain injuries such as frontal lobe lesion may
cause impulsive behaviors as well. 10
On the other hand, dysregulation is an indicator of irritation and less attention. While
impulsivity is positively associated with several mental health disorders and even suicide, 9
dysregulation is related to risky behaviors such as eating disorders. 11
1.2.4 Self-esteem
Self-esteem is one’s attitude of himself/herself, 12 and even though self-esteem is
interior, it can be impacted by role models or by peers. 13 Self-efficacy is an individual’s belief
that he/she is able to manage tasks. 13 Self-esteem and self-efficacy play a major role in
people’s achievement in goals, missions, and challenges. 13 Yorra 13 investigated the level of
self-efficacy and self-esteem in 399 third-year pharmacy students whose grade point
averages (GPAs) were equal to or higher than 3.0 in the New England area in the US. He
found that the school that students attended and the hours that students got paid were
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significantly correlated to self-esteem level. Also, self-esteem is usually correlated to body
image among young adults. 14, 15 Skorek et al. 15 examined the relationship between
personalities (conscientiousness, emotional stability, extraversion, agreeableness, openness),
body esteem level, and self-esteem level among undergraduate students in Central California.
They found that female participants had lower emotional stability and body esteem than
males. Higher personality stability was associated with higher self-esteem and higher body
satisfaction. The findings indicate that gender, personality, and body image may affect
individuals’ self-esteem.
1.3 Risk Factors for Psychological Impairments
1.3.1 Excess Body Weight
Anxiety, depression, impulsivity/dysregulation, and low self-esteem is associated with
excess weight, 4, 9, 11, 14, 15 excess weight may be a risk factor for poor mental health. People
who have a body mass index (BMI) of 25-29.9 are classified as overweight and those who
have a BMI of 30 and above are classified as obese. 16 Obesity affects 78.6 million people,
which is equal to 33% of the population in the United States, and it is predicted to increase to
50% by 2030. 17 In Arkansas, 20.7% of young adults (18-25 year olds) and 34.6% of adults
(20 years old and older) had obesity in 2015. 18 Moreover, excess weight is associated to
poor mental health outcomes such as depression, low self-esteem, peer victimization, and
poor quality of life. 19
1.3.2 Nutrient Deficiencies
While excess weight may contribute to poor mental health, deficiency in vitamins and
minerals is another risk factor. 20 Vitamins function as coenzymes and antioxidants to prevent
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damage in the brain. 12 For example, the B vitamins, a group of water-soluble micronutrients,
play an important role in cognition and brain function. Pyridoxine (vitamin B6), folate (vitamin
B9), and cobalamin (vitamin B12) influence blood homocysteine (a sulphur-containing amino
acid) level. Some mechanisms that result in an increase of mental illness outcomes are also
associated with elevated homocysteine. 20 Pyridoxine occurs naturally in the form that exists
in food, in additional use, or in dietary supplements. The natural forms are pyridoxine,
pyridoxal, pyridoxamine, and respective 5’-phosphate esters. Pyridoxal 5’-phosphate is the
active form of pyridoxine that serves as a carbonyl-reactive coenzyme in many reactions of
amino acid metabolism. 20-22 Among those metabolic pathways, there is one pathway that
lowers homocysteine levels.
Also, pyridoxine facilitates the formation of epinephrine, norepinephrine, serotonin,
and γ-amino butyric acid (GABA). 12 They are all neurotransmitters in the central nervous
system. Moreover, it assists in the synthesis of taurine that concentrates in the brain and in
the conversion of tryptophan to niacin by kynureninase. 12
Second, folate is a kind of vitamin that is involved in various metabolic pathways such
as deoxyribonucleic acid (DNA) synthesis, methylation, and methionine regeneration. 13 It is
commonly used to lower cases of neural tube defects in infants. In addition, it is used in
1-carbon metabolism by tetrahydrofolate (THF) to maintain proper S-adenosylmethionine
(SAM) level. 20 THF receives and donates methyl groups, and methionine synthase requires it,
together with cobalamin, to attach a methyl group to homocysteine, so that SAM is formed.
Typically, since this pathway keeps the SAM level stable, homocysteine can be removed by it,
so that a damaging effect on brain function is prevented. SAM serves as the methyl group
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donor in several methylation reactions and causes oxidative stress through several
mechanisms. 13
Furthermore, cobalamin has two forms of coenzymes, methylcobalamin and
deoxyadenosylcobalamin, serving the enzymes called methionine synthase and
methylmalonyl-CoA mutase. 20 Cobalamin deficiency causes folate being trapped in the
methyl-5 form and reduction of DNA synthesis, which may influence brain function.
On the other hand, pyridoxine, folate, and cobalamin prevent oxidation by reducing
oxidative stress resulting from mechanisms that involve SAM 13, 20; antioxidants prevent
oxidation, a damage that is caused by oxygen and produces free radicals and other reactive
oxygen species. 20 However, our brain is too vulnerable to defend against oxidation due to
lipid-rich and metabolically active mechanisms without a powerful system for antioxidation;
therefore, antioxidants play a critical role to protect the brain. 20 Vitamins A, C, and E are
powerful dietary antioxidants that can prevent cytotoxicity due to free radicals, sweep out
reactive oxygen species, and upregulate enzyme activity of antioxidants. Specifically, vitamin
C provides an electron and acts as an oxidant to terminate the free radical chain reaction and
becomes a vital defender for the brain due to high levels of vitamin C in the plasma of
cerebrospinal fluid and the brain. 23 Vitamin C also renovates radical removal of vitamin E. 24
Moreover, α-tocopherol, a type of vitamin E, is typically the main format in the brain, and
neurological disease will happen if people lack it. Furthermore, vitamins E and A prevent lipid
peroxidation, which is paramount for membrane conservation. 23
Additionally, minerals influence brain function and mood in multiple ways. For
example, when neurotransmitters dopamine, serotonin, and norepinephrine react with
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oxygen, iron and copper ions release; after that, free radicals catalyze and cause damage to
the brain. 20 Furthermore, dietary magnesium, copper, and zinc act as cofactors of enzymes
that prevent damage from oxidative stress. 20 Magnesium is involved in multiple metabolic
pathways, so normal function of the nervous system and release of neurotransmitters are
dependent on magnesium. 25 Copper is the cofactor of an antioxidant enzyme copper, zinc
superoxide dismutase (CuZnSOD). 26 Meanwhile, zinc plays a role for many enzymes that
maintain brain zinc homeostasis. 27 Some underlying pathways have been investigated;
however, some remain unclear.
Therefore, micronutrient deficiency may associate with poor psychological health.
Given critical roles of vitamins and minerals in brain function, brain development, DNA
synthesis, and mood, MVM supplements may have a positive effect on mood improvement.
However, the actual effect is still a debate. Evidence shows that MVM supplements could
help decrease antagonistic and violent behaviors in children and adults. 28 Additionally,
evidence from a meta-analysis suggests that MVM supplementation reduced levels of stress,
psychiatric symptoms, anxiety, confusion and fatigue, but not depression. 29

2 Existing Studies of MVM Use and Psychological Health among Adults
Several human intervention studies have tested whether MVM supplements may
improve psychological outcomes among adults aged 18 years and above. However, others
suggested that MVM supplements have no significant effect on mental health improvement.
Among those, some are randomized, placebo-controlled trials, while some are
pretest-posttest studies.
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2.1 Randomized, Double-Blind, Placebo-Controlled Design
2.11 Swisse Vit® Supplement
Harris et al. 30 hypothesized that the MVM supplement would improve symptoms of
depression. In this study, 50 healthy male participants who were 50-69 years old were
provided with a supplement called Swisse Men’s Ultivite® which had multivitamins, herbal
extracts, and minerals, or a placebo for 8 weeks. Data were collected through General Health
Questionnaire (GHQ), Depression Anxiety Stress Scale (DASS), as well as Perceived Stress
Scale (PSS), Profile of Mood States (PMS), and Visual Analog Mood Scales (VAMS). They
found that there was a significant difference for GHQ scores between treatment and
placebo-controlled groups; particularly, the alternative from baseline in the treatment group
was higher than placebo-controlled group. Also, a statistically significant treatment effect
across the intervention was discovered for the total DASS score but not for any subscales
(depression, anxiety, and stress). Moreover, the MVM group had a more positive score
change in alert scores on VAMS. Finally, they concluded that there was a tendency for better
performance in the multivitamin-mineral supplement group.

30

Pipingas et al. 31 also investigated the effect of Swisse Ultivite ® on mood. One hundred
and thirty-eight healthy young adults aged 20-50 years participated in this study for 16 weeks.
However, males were provided the formula for men and females were provided the one for
women. The findings showed no significant difference on the scores of the General Health
Questionnaire (GHQ), Profile of Mood States (POMS), Pennebaker Inventory of Limbic
Languidness (PILL), Chadler Fatigue Scale (CFS), Bond-Lader Visual Analogue Scales (VAS)
between the MVM supplement group and the placebo-controlled group. However, compared
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to the placebo-controlled group, MVM tended to reduce the score in the subscales of VAS
(significant in stress, anxiety, and physical fatigue). During weeks 1-4, the rates of VAS stress
scale and anxiety scale in the MVM group were significantly lower than the
placebo-controlled group. During both weeks 5-8 and weeks 9-12, VAS physical fatigue rating
was significantly less in the MVM supplement group in comparison to the placebo-controlled
group. 31
Meanwhile, Sarris et al. 32 analyzed the qualitative data from 114 participants in this
study. Participants were asked about positive and negative experiences after taking the
supplement. The positive experiences included domains such as general mental benefit;
improved concentration, attention, and/or memory; increased calmness or relaxation; better
mood and emotional state; general physical benefit; improved sleep; more energetic or alert;
better health or immunity; dermatological benefit; and increased/better appetite. The negative
experiences included impaired concentration or attention, being stressed or anxious, more
moody emotions, impaired sleep, being more fatigued or drowsy, poorer health or immunity,
upper gastrointestinal complaints, indigestion or nausea, dermatological complaints,
gynecological effect, and unintended weight gain. The supplement group reported at least
one positive experience such as energy and mental alertness as well as increase in mood
and emotional wellbeing. Also, the supplement had no major adverse effects. 32
After that, Macpherson et al. 33 investigated the effect of Swisse Women’s 50+ Ultivite ®
on the mood and cognition of 76 healthy women aged 50-75 years. Mood was assessed by
the Depression Axiety Stress Scale (DASS); State Trait Anxiety Inventory (STAI)-State
Anxiety Scale; Bond-Lader Visual Analogue Scale (VAS); Stress, Anxiety, Concentration,
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Physical Fatigue and Mental Fatigue Visual Analogue Scales. They also examined cognitive
effects using the Swinburne University computerized cognitive assessment battery, including
a series of tasks related to reaction time, stroop test, recognition memory, and working
memory. The results showed that the MVM supplement benefited mood 1-2 hours after
consumption. The rating of overall mood on DASS improved and this effect seems to be due
to stress reduction. On VAS, the supplement was associated with decreased rating of stress
and increased rating of calmness.

33

2.12 Berocca® Supplement
The supplement Berocca® contains B vitamins, vitamin C, calcium, magnesium, and
zinc. Compared to Swisse Vit®, it did not have vitamin D3 or herbal extracts.
Carroll et al. 34 examined the possible mental effect of a MVM supplement using
Berocca®. Eighty men aged 18-42 years were provided with the supplement or a placebo for
28 days. Data were collected using the assessments including the GHQ, PSS, Hospital
Anxiety and Depression Scale (HADS), a physical symptom checklist, and a dietary
questionnaire. Plasma zinc concentration was also assessed. Moreover, participants
completed the general rating scales for anxiety, depression, tension, tiredness, and inability
to concentrate (basically indicated 1 for not at all and 7 for very). Also, they self-reported the
effect of the MVM. The findings indicated that the MVM supplement was associated with
psychological state improvement, reductions in anxiety, less perceived stress, rating of less
tired and better concentrations, and less physical or somatic symptoms.

34

Another double-center study also used Berocca® by Schlebusch et al.

35

to investigate

its effect on mood improvement. Three hundred participants aged 18-65 years completed a
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stress symptom checklist as well as a biographical questionnaire, the Hamilton Anxiety
Rating Scale (HARS), the Psychological General Well-being Schedule (PGWS), the Visual
Analogue Scale (VAS), and Berocca Stress Index (BSI). Also, collateral information from
participants’ close relatives was obtained, and participants completed the daily patient diary.
Participants were provided the MVM supplement or a placebo for 30 days. Schlebusch et al. 35
found that there were no differences between the MVM supplement and placebo-controlled
groups regarding demographics and stress scores at baseline. However, both the scores of
the two groups improved between baseline and the end of treatment. In subgroups of 18-44
and 45-65 year olds, gender and ethnicity showed no significant impact on the overall study
outcome. However, the score improvement on BSI, HARS, PGWS, and VAS was statistically
significant. Also, the difference of scores was greater in MVM supplement group compared to
the placebo-controlled group. Importantly, this beneficial effect lasted for the whole day.

35

Kennedy et al. 36 examined the effect of Berocca ® on mood and cognition with 215
men aged 30-55 years for 33 days. The Profile of Mood States (POMS), the Perceived Stress
Scale (PSS), the General Health Questionnaire (GHQ), the Bond-Lader Mood Scales, and
the Energy Visual Analogue Scales (VAS) were used to measure the status of mood.
Meanwhile, participants were asked to complete a series of tasks including serial subtractions,
rapid visual information processing task, subjective mental fatigue scale, stroop task, and
Wisconsin card sort task to measure the cognitive function. The results showed that in the
MVM supplement group participants consumed more vegetables and fruits than those in the
placebo-controlled group. Also, participants in the MVM supplement group rated lower
subjective stress (PSS scores) and increased vigor (physical strength and good health;
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POMS subscale) compared to placebo-controlled group. If vegetable and fruit consumption
was considered, the score in GHQ significantly decreased. Moreover, the serial threes correct
rate in the serial subtractions significantly increased, while the mental tiredness significantly
decreased. This indicated that participants’ cognition and memory improved. Within the
previous study, Kennedy et al. 36 also investigated the effect using a mobile phone
assessment in the prior 4 weeks. The findings indicated increased alertness in the evening
after a 14-day intervention and the increased alertness throughout daytime after a 28-day
intervention. Furthermore, the mental stamina and concentration rate in the VAS increased
after work with the improved overall physical stamina rate.

36

Recently, White et al. 37 used a different Berocca® that contained more thiamine than
the former one to examine its potential beneficial effect on mood in young adults. Fifty-five
participants aged 18-40 years took the daily supplement for 28 days. Participants completed
the Proﬁle of Mood States (POMS), Perceived Stress Scale-10 (PSS), Visual Analogue Mood
Scales (VAS), State-Trait Anxiety Inventory (STAI) Meanwhile, blood samples were collected
to further examine the level of serum vitamin B6, folate, vitamin B12, homocysteine (Hcy),
and high sensitivity C-reactive protein. The results suggested that compared to
placebo-controlled group, MVM supplement consumption lowered serum Hcy level and
increased vitamin B6 and vitamin B12. Also, MVM supplementation was associated with
lower depression-dejection scores, but not associated with change in cognitive assessment.37
Overall, the findings from the five articles above indicate that the MVM supplement Berocca®
may have a positive effect on mood in adults. Also, it might improve people’s performance in
work and study.

13

2.13 Other Supplements
In 1995, Benton et al. 38 conducted a study to investigate the influence of a vitamin
supplement on cognitive function. The supplement contained 9 vitamins including thiamin,
riboflavin, and pyridoxine and the dose was 10 times of the recommended dietary allowance
(RDA). Two hundred and nine participants aged 17-27 years were provided with the
supplement or a placebo for 12 months. Also, a series of psychometric tests were
administered. Moreover, blood was collected to analyze serum vitamin A and vitamin E levels
as well as plasma ascorbic acid concentration, among others. The findings suggested that
vitamin status was correlated with cognitive functioning in both females and males. The
correlation was more obvious after 12 months than after 3 months. Furthermore, the
correlation was more significant in females than in males. In this study, Benton et al. 38 also
examined the effect of the supplement (9 vitamins; 10 times of RDA) on mood. The Profile of
Mood States (POMS) and the General Health Questionnaire (GHQ) were used to measure
the mood of participants. The results indicated that a high dose of vitamins may have a
long-term positive effect on women’s mood.

38

Similarly, Haskell et al. 39 published another article in 2010 investigating the effect of
MVM supplementation using Supradyn® on fatigue and cognitive function in healthy women.
Two hundred and sixteen females aged 25-50 years participated in this study taking the
supplement or a placebo for 3 months. Haskell et al.

39

used various measurements and

cognitive testing tasks as well as physiological assays to collect data. The results showed
reduced tiredness measured in the Visual Analogue Scales (VAS) and increased math score
as well as increased accuracy of performance in Stroop Color-Word and speed of memory
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searching in the MVM group. In contrast, there was no significant beneficial effect on
improvement of fatigue and mood.

39

Also, Gosney et al. 40 in 2008 explored the association between MVM supplementation
and depression and anxiety symptoms among elderly people. Seventy-three healthy elder
people from 11 nursing homes were treated with a MVM supplement or a placebo for 8 weeks.
Both the supplements and placebos were supplied by a company called Recip AB, Sweden.
Data were assessed by the Montgomery-Asberg Depression Rating Scale (MASRS), and
Hospital Anxiety and Depression Scale (HADS). Gosney et al.

40

found that in the MVM group

the scores on the depression subscale of HADS tended to decrease, while the scores on the
anxiety subscale of HADS tended to significantly reduce in the placebo-controlled group. Also,
participants with severe depression showed an increase in selenium level and a decrease in
depression. The results only indicated that selenium might ameliorate depressive symptoms
in older population.

40

Additionally, in 2013 Lewis et al. 41 investigated the relationship between a vitamin
B-complex supplement called Max Stress and people’s mental health. Sixty depressive adults
over 18 years old had the supplement for 60 days. Participants completed the Beck Anxiety
Inventory (BAI), Beck Depression Inventory (BDI), and the assessment related to quality of
life and physical activity level at baseline, and after 30 and 60 days. The findings suggested
that Max Stress can decrease depressive and anxiety symptoms as well as improve quality of
life in adults with depression. 41 Notably, the beneficial effect tended to be short-term and
continuously decrease over the study period.
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Moreover, Kennedy et al. 42 examined the effect of a nutrient enriched breakfast bar
which contained α-Linolenic acid, L-tyrosine, L-theanine, vitamins, minerals and 21.5 mg of
caffeine on mental health among healthy young adults. Ninety-five participants took the
breakfast bar or a placebo for 8 weeks. Cognitive function was measured by multiple tasks
including the cognitive demand battery (CDB) using the Computerised Mental Performance
Assessment System (COMPASS); at the same time, mood was measured by the Depression,
Anxiety and Stress Scales (DASS). The consumption of the nutrient-enriched breakfast bar
had an acute effect on improvement of cognitive impairments (attention, working and episodic
memory as well as executive function). Also, alertness was significantly and acutely improved
due to the nutrient enriched breakfast bar. However, there was no chronic effect on cognitive
or mood improvement. 42
Furthermore, Evans et al. 43 conducted a study to investigate the effect of a beverage
called Zeal Wellness on mood. The beverage contained various compounds such as vitamins
and minerals as well as rice, bran, fruit, and vegetable extracts. Ninety-nine participants with
moderate stress aged 18-65 years drank one dose or two doses of the beverage or a placebo
for 4 weeks. Participants completed the Proﬁle of Mood States (POMS) to measure the mood
status at screening, baseline, and days 8, 15, and 29; meanwhile, blood samples were
collected. After analyzing the Proﬁle of Mood States-Total Mood Disturbance (POMS-TMD)
score and blood samples, Evans et al.

43

found that, compared to the combined placebo and

1-dose daily beverage group, POMS-TMD scores and anger-hostility mood symptoms
signiﬁcantly decreased in the 2-dose daily beverage group. Also, the POMS iceberg proﬁle
shifted to a healthy proﬁle. 43 Therefore, this beverage had beneficial effects on mental health.
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2.2 Pretest-posttest Design
Participants usually report positive or negative results based on their own bias. This
may influence the results away from the truth. Therefore, without a control group,
pretest-posttest study design has a risk of providing false positive or false negative results,
and is considered a relatively weaker study design.
Kimball et al. 44 investigated the relationship between MVM supplement and mood.
More than 10,000 participants aged 18-95 years were provided Vital 2 Platinum for an
average of 12 months. The Vital 2 Platinum contained omega-3 fatty acids (EPA and DHA),
vitamin C, vitamin B12, probiotics, and vitamin D3 drops. Questionnaires such as the
European Quality of Life Five Dimensions (EQ-5D) and the Targeted Symptoms List (TSL)
were used and BMI and serum vitamin D and vitamin B 12 level were examined. The results
suggested that participants who had either severe/extreme or no/slight/moderate depression
and anxiety reported improvement in depression and anxiety. Also, vitamin D intake and
physical activities were significantly associated with improvement in depression and
anxiety.44 Therefore, nutritional supplementation may be beneficial to people who suffer from
depression and anxiety on improvement of moods.
Also, Han et al. 45 examined the effect of a MVM beverage called Lifelong Vitality Pack
on mood. Sixteen participants with average age of 42 years were given Lifelong Vitality Pack
containing multivitamins, multiminerals, herbal, and an omega-3 fatty acids supplement
infused with essential oils for 2 months. Blood samples were used to examine biomarkers
related to cardiovascular health, antioxidant status, inflammation, and blood glucose
regulation. Also, participants completed a 16-item survey to assess physical and mental
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health. The results showed that HDL cholesterol, LDL/HDL cholesterol ratio, fasting insulin,
homocysteine, serum vitamin E, EPA, and the arachidonic acid (AA)/EPA ratio were improved
after 2-month supplementation. Moreover, there was a significant improvement on back and
muscle pain, cold and flu incidence, anxiety, frustration, and irritation as well as mental clarity,
energy, motivation, control, balance, and happiness.

45

3 Summary and Recommendation
Despite the critical weakness in the study design for pretest-posttest studies, 44, 45
other randomized, double-blind, placebo-controlled studies above provide some interesting
results. However, they still have limitations. First, participants’ ages widely ranged in most
studies. The widest age range was from 18 to 65 years old. 43 However, young adults aged
18-24 year are at a unique developmental stage. 3 They are physically and socially different
from adults aged over 24 years as we discussed above. Also, the MVM supplements which
participants consumed in these studies were different. Some supplements contained not only
vitamins and minerals, but also herbal extracts, plant extracts, fatty acids, amino acids, etc.
Two had a high concentration of vitamins which human beings do not regularly take.

38, 41

Moreover, the lengths of intervention varied. The lengths were from 28 days to 12 months.
Furthermore, weight is mostly absent in those studies. Weight is associated with mental
health as discussed above. Therefore, the attention to overweight/obese status may be
required in future studies. Given the importance of investigating the effect of MVM on young
adults’ mood, we utilized the supplement that has the same components as Berocca ® (only
containing vitamins and minerals) and examined its effect on improvement of: anxiety,
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depression, impulsivity/dysregulation, and low self-esteem among healthy young adults. Our
objectives were 1) to investigate whether a 30-day MVM supplementation using supplements
containing only vitamins and minerals improves mental health in young adults; 2) to examine
the effect of supplementation in overweight/obese group. Our hypotheses were 1) our MVM
supplementation will decrease symptoms of anxiety, depression, dysregulation, and low
self-esteem in young adults; 2) our MVM supplementation will decrease symptoms of anxiety,
depression, dysregulation, and low self-esteem in young adults in overweight/obese BMI
group.

19

Chapter 2
5 Methods
5.1 Participants and Randomization
This study was approved by the University of Arkansas Institutional Review Board for
human subject research (Approval #1709073942), and each participant signed informed
consent form before enrolling in the study. We promoted the study through flyers at a
mid-south public university beginning in October 2018 and ending in May 2019.
This study was a randomized, double-blind, placebo-controlled trial. There were 272
potential participants, but 121 of them failed to meet the inclusion criteria, and 20 of them
were eligible but never enrolled. One hundred and thirty-one participants were enrolled at
baseline. We measured their height and weight, and stratified them into two groups by BMI.
One group had participants with normal BMI (18.5-24.9), and the other group had participants
with overweight/obese BMI (≥25). Those who were underweight (BMI<18.5) were ineligible
for our study. We further randomly assigned participants to take a MVM supplement or a
placebo for 30 days. Participants completed questionnaires regarding mental health-related
outcomes at baseline and on Day 30. Participants who were U.S. citizens were compensated
a total of $100 in the parent study given incrementally when each questionnaire required by
the parent study was completed. The compensation schedule was that participants received
$10 after the completion of questionnaires at baseline, $15 after the completion of
questionnaires on Day 2, $20 after the completion of questionnaires on Day 3, $25 after the
completion of questionnaires on Day 15, and finally $30 after the completion of
questionnaires on Day 30. The incremental approach was chosen to promote compliance
retention. Due to university payment policy and tax policy, participants who were non-citizens
20

were paid in total at the end of the study. They needed to be taxed at 30% of the $100.
5.2 Inclusion and Exclusion Criteria
Inclusion criteria included 18-24 years old; full-time or part-time students, or at least
working part-time; and willing to avoid taking other supplements during the study. Exclusion
criteria included underweight; diagnosis with malabsorption or related gastrointestinal
disease such as Crohn’s disease or inflammatory bowel disease; diagnosis with diseases
related to impaired liver or renal function; diagnosis with a mental illness; taking prescription
medications related to mental illnesses. We determined potential participants’ eligibility
through a phone screening and scheduled their study timeline on their consenting day.
5.3 Supplement
The supplement contained the same components as the supplement Berocca®. It had
15 mg thiamin (vitamin B1), 15 mg riboflavin (vitamin B2), 50 mg nicotinamide (vitamin B3), 23
mg pantothenic acid (vitamin B5), 10 mg pyridoxine hydrochloride (vitamin B6), 10 μg
methylcobalamin (vitamin B12), 500mg Vitamin C, 150μg biotin, 400μg folic acid, 100 mg
calcium, 100 mg magnesium, and 10 mg zinc. Participants took the supplement or a placebo
daily for 30 days. Both the supplement and placebo were provided by a local compounding
pharmacy.
5.4 Assessment
Participants completed questionnaires through Qualtrics at baseline and on Day 30.
The questionnaires included demographic questions, Beck Anxiety Inventory (BAI), Center
for Epidemiologic Studies Depression Scale (CES-D), Abbreviated Dysreglation Inventory
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(ADI), and a single item for self-esteem (SISE). On Day 30, participants completed
questionnaires after they took the active supplement or a placebo in the morning.
5.41 Participants’ demographic characteristics
Participants completed a short demographic survey asking about their age, gender,
student full- or part-time status, year in college, highest level of education completed,
students’ employment status, geographic living location, highest level of education students’
mother completed, highest level of education students’ father completed, and food security.
The survey included questions such as “What is your age in years?”, “What is your gender?”,
“Are you a full-time or part-time student?”, “What year are you in college?”, “What is your
highest level of education completed?”, “What is your employment status?”, “What is your
geographic living location?”, “What is the highest level of education your mother completed?”,
and “What is the highest level of education your father completed?” U.S. Household Food
Security Survey Module: Six-Item Short Form Economic Research Service, USDA was used
to assess participants’ food security level. 46 A higher score indicated higher food security.
Also, food security status has three categories of “high or marginal food security”, “low food
security”, and “very low food security”. A study of Gulliford et al. 47 revealed item-score
correlations of the scale were from 0.52 to 0.79 and revealed a good Cronbach’s α= 0.87.
Participants provided this demographic information at baseline. The remaining
questionnaires were completed at all time points.
5.42 Beck Anxiety Inventory (BAI)
The BAI is a brief measure of anxiety symptomology developed to discriminate
between anxiety and depression with a 21-item self-reported questionnaire assessing
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symptoms related to mental disorders such as nervousness, dizziness, inability to relax, etc. 48
The questionnaire asked how much participants have been bothered by anxiety symptom
listed below during the past week, including today. The answers included “numbness or
tingling”, “terrified or afraid”, “hands trembling”, etc. 48 The score was calculated by summary
of each item. A score of 0-21 indicated a low level of anxiety; a score of 22-35 indicated a
moderate level of anxiety; a score of 36 and above indicated potentially concerning levels of
anxiety. Items on the inventory have good internal consistency (α= 0.92) and test-retest
reliability (α= 0.75). The items are correlated with the revised Hamilton Anxiety Rating Scale
(0.51) and correlate with the Hamilton Depression Rating Scale (0.25). 48
5.43 Center for Epidemiologic Studies Depression Scale (CES-D)
The CES-D is a 20-item self-reported measure of characteristic attitudes and
symptoms of depression developed by National Institute of Mental Health. The CES-D is
correlated with other depression measures and has high internal consistency (α= 0.90). 49
The questionnaire asked participants to indicate how often they have felt or behaved the way
listed below during the last week. The answers included “I was bothered by things that
usually don't bother me.”, “I had trouble keeping my mind on what I was doing.”, “I felt
depressed.”, etc. 49 The score was summed, and a higher score indicated the presence of
more symptomatology.
5.44 Abbreviated Dysregulation Inventory (ADI)
The ADI is a 30-item self-reported measure of aspects of temperament and behavior.
The scores of scale reflected three aspects of dysregulation: behavioral dysregulation (BD),
cognitive dysregulation (CD), and emotional dysregulation (ED). 50 It was rated on a 4-point
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scale. “0” indicated “Never True”, and “3” indicated “Always True”.

50

The scores were

summed in each subscales, and a higher score indicated the presence of more
symptomatology. Items on BD and ED have good internal consistency (behavioral
dysregulation α= 0.87, emotional dysregulation α= 0.87). 51, 52 Evidence also revealed good
validity of ADI items. 51-53
5.45 Single Item for Self-Esteem (SISE)
The single item for self-esteem (SISE) was a question asked if participants had high
self-esteem and was rated on 5 points from strongly agree to strongly disagree. Evidence
showed that the SISE is as valid and reliable as a scale. 54 It can be an alternative to the
Rosenberg Self-Esteem Scale (RSE) in adults. 54
5.46 Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA 24® 2016)
The ASA 24® 2016 is developed by the National Cancer Institute. Participants
provided dietary information over the previous day through the online system. They
completed the system each time with the survey. The 24-hour dietary recalls were collected
so that caffeine, fruit, and vegetable intake could be controlled for in data analyses due to
their potential influence on mental health and the effect of the supplementation on mental
health. 55, 56 Participants’ caffeine intake was recorded in the unit of mg. Participants’ fruit and
vegetable intakes were recorded in the unit of cup eq./day. Fruits intake included total intact
fruits (whole or cut) and fruit juices. Vegetables intake included total dark green, red and
orange, starchy, legumes, and other vegetables.
5.5 Statistical Analysis
Data were analyzed by SPSS 24 (IBM Inc., Chicago, IL, USA). We used chi-square
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and independent sample t-test to test if characteristics of participants were equal. Also, we
used repeated measures ANCOVA to examine the change between mean differences of
scores from BAI, CES-D, ADI, and SISE in college-age young adults before and after the
intervention. Box’s test of equality of covariance matrices tested the assumption that the
covariance matrices were equal (p> 0.01), and Levene's test of equality of error variances
tested if variances between the groups were equal (p> 0.05). First, in order to examine the
overall effects of supplementation on mental health-related outcomes, we considered score
changes of BAI, CES-D, ADI, and SISE from baseline to Day 30 as within-subject factors, and
participants’ treatment/placebo group as a between-subject factor. This analysis tested if
there was an overall effect period. Data were adjusted by covariates such as gender, BMI,
food security score, caffeine intake, and fruits and vegetables intake. After that, in order to
examine the effect of supplementation in participants with excess weight, we selected
overweight/obese BMI group. We considered score changes of mental health-related
outcomes from Day 0 to Day 30 as within-subject factors and participants’ treatment/placebo
group as a between-subject factor. Data were adjusted by the same covariates, except BMI.
Since our hypotheses were directional, a one-tailed p-value less than 0.05 was considered
significant. Partial η2 represented the effect size (small: 0.01, medium: 0.06, large: 0.14). A
small effect size means that where a real effect, while a large effect size shows a big enough
and consistent enough effect.

57

Within subject results indicated whether there were

differences within the placebo-controlled group from baseline to Day 30 or whether there
were differences within the MVM supplementation group from baseline to Day 30. Between
subject results indicated whether there were differences between the placebo-controlled
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group and the MVM supplementation group pre- and post-intervention.
The prevalence of anxiety in females is higher than males. So is the prevalence of
depression and self-esteem. The majority of our sample was women (n=131; 80.15%).
Therefore, gender was taken into consideration a covariate. As we previously discussed,
excess weight may be a risk factor for poor mental health. Thus, participants’ BMI was also a
covariate we adjusted. Food security level may affect people’s food choice and eating habits.
Food insecurity is usually linked to hunger and may influence growth and health status.

58

In

our study, more than 80% of participants had no food insecurity problems. Nontheless, we
included this variable in the analysis. Fruit and vegetable intake is another covariate that we
adjusted for in the analysis because intake of raw fruits and vegetables was related to less
depressive symptoms, higher positive mood, and higher life satisfaction. 55 Moreover,
evidence suggests that 200-250 mg caffeine intake elevates mood, but higher doses (>600
mg) may increase anxiety level.

56

Hence, we also adjusted for caffeine intake.
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Chapter 3
6 Results
The preliminary data were from October 2018 to May 2019. There were 131
participants at baseline. Among those, 103 participants completed all of the questionnaires
for anxiety, and 102 completed all of the questionnaires for depression, dysregulation, and
self-esteem level.
6.1 Demographic Characteristics
Means and standard deviations are presented in Table 1 for participants’ age, body
mass index (BMI) at baseline. The sample (n=131) was compromised of 80.15% females and
19.85% males with a mean age of 20.59 years (SD=1.77). There were 69 participants in
MVM supplementation group and 62 in placebo-controlled group with the overall mean BMI of
25.92 (SD=6.21). The mean BMI in MVM supplementation group was 25.87 (SD=6.01), and
the mean BMI of placebo-controlled group was 25.97 (SD=6.48). The mean age of MVM
supplementation group was 20.70 years (SD=1.76), while the mean age of
placebo-controlled group was 20.53 years (SD=1.79). Characteristics of the study sample
(e.g., gender, year in college, etc.) are shown in Table 2. Most of the participants (n=129;
86.81%) were college students. Similarly, more than 80% of the participants lived in urban
areas (n=131; 86.26%) or had high or marginal food security (n=126; 84.13%). More than half
of the participants’ mother or father had a bachelor’s or higher degree (n=131; mother: 62.6%;
father: 58.78%). Generally, the supplementation group and placebo-controlled group had no
difference in age, BMI, gender, year in college, living location, food security status, and
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participants’ parents’ education level using independent sample t-test and chi square
(p>0.05). This suggests that the two groups were well matched.

Table 1 Means, Standard Deviations of Participants’ Age and BMI and T-Tests Comparing
MVM Supplementation Group and Placebo-Controlled Group.
Total Sample
MVM
Placebo
Variable
t
N
Mean (SD*)
N
Mean (SD*)
N
Mean (SD*)
Age
131 20.59(1.77)
69 20.70(1.76)
62 20.53(1.79)
-0.526
BMI (m/kg2)
131 25.92(6.21)
69 25.87(6.01)
62 25.97(6.48)
0.092
* SD, Standard deviation

Table 2 Sample Size and Percentage in Participants’ Gender, Year in College, Living Location,
Food Security Status, and Parents’ Education Level with Chi-Square Comparing MVM
Supplementation Group and Placebo-Controlled Group.
N Total Sample
Variable

Total MVM Placebo

N in Each Category
Category

MVM

26
(19.85%)
105
(80.15%)

14
(20.29%)
55
(79.71%)

12
(19.35%)
0.018
50
(80.65%)

Freshman/
51
Sophomore
(39.52%)
Junior/Senior 61
(47.29%)
Graduate
16
student
(12.40%)
Not a college 1
student
(0.79%)
Urban
113
(86.26%)
Rural
18
(13.74%)
High or
106
marginal
(84.13%)
Low
14
(11.11%)
Very low
6
(4.76%)

25
(36.77%)
34
(50.00%)
8
(11.76%)
1
(1.47%)
58
(84.06%)
11
(15.94%)
54
(84.38%)
5
(7.81%)
5
(7.81%)

26
(42.62%)
27
(44.26%)
4.100
8
(13.12%)
0

Male
Gender

Year in
college

Location

Food
security

131

129

69

68

62

61

131

69

62

126

64

62

Female
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Placebo

χ²

Total

55
(88.71%)
0.596
7
(11.29%)
52
(83.87%)
9
9.575
(14.52%)
1
(1.61%)

Table 2 (Cont.)
Variable

N Total Sample
Total MVM Placebo

Mother’s
131
education

Father’s
131
education

69

69

62

62

Category
Up to
high
school
Some
post
high
school
training
College
graduate
Master’s
degree
or higher
Up to
high
school
Some
post
high
school
training
College
graduate
Master’s
degree
or higher

N in Each Category
Total
MVM
Placebo
26
13
13
(19.84%) (18.84%) (20.97%)

χ²

23
13
10
(17.56%) (18.84%) (16.13%)
2.106
59
(45.04%)
23
(17.56%)

31
(44.93%)
12
(17.39%)

28
(45.16%)
11
(17.74%)

31
16
15
(23.66%) (23.18%) (24.19%)
23
13
10
(17.56%) (18.84%) (16.13%)
10.245
43
(32.83%)
34
(25.95%)

20
(28.99%)
20
(28.99%)

23
(37.10%)
14
(22.58%)

6.2 Descriptive Statistics of Unadjusted Pre- and Post-Intervention Outcomes
One hundred and three participants completed all the anxiety questionnaires, and 102
participants completed all questionnaires testing symptoms of depression, behavioral
dysregulation, cognitive dysregulation, emotional dysregulation, and self-esteem level. There
were 53 participants in MVM supplementation group and 50 participants in placebo-controlled
group regarding completion of BAI, whereas 53 participants in MVM supplementation group
and 49 participants in placebo-controlled group completed CES-D, ADI (BD, CD, ED), and
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SISE. Unadjusted means and standard deviations of score changes for mental health-related
assessments from baseline to the last day of the intervention are indicated in Table 3. In
overweight/obese BMI group, 44 participants completed questionnaires for anxiety symptom,
depressive symptom, behavioral dysregulation, cognitive dysregulation, emotional
dysregulation, and self-esteem level. There were 21 participants in MVM supplementation
group and 23 participants in placebo-controlled group completed BAI, CES-D, ADI (BD, CD,
ED), and SISE. Presented in Table 4 are the unadjusted means and standard deviations of
score changes for assessments on Day 0 and Day 30 in overweight/obese BMI group.

Table 3 Means, and Standard Deviations of Scores in BAI, CES-D, ADI (BD, CD, and ED),
and SISE at Baseline and on Day 30.
Assessment

Group

N

MVM
Placebo
MVM
CES-D
Placebo
MVM
BD
Placebo
MVM
ADI
CD
Placebo
MVM
ED
Placebo
MVM
SISE
Placebo
* Unadjusted mean
** SD, Standard deviation

53
50
53
49
53
49
53
49
53
49
53
49

BAI

Baseline Mean* (SD**)
1.09 (0.30)
1.06 (0.24)
9.42 (3.86)
8.65 (2.95)
6.60 (5.39)
6.82 (4.52)
21.21 (5.74)
21.10 (5.34)
5.08 (4.41)
5.27 (3.86)
1.38 (0.95)
1.12 (0.78)

Day 30 Mean* (SD)
1.02 (0.14)
1.02 (0.14)
7.81 (3.96)
6.39 (3.38)
5.34 (6.00)
4.90 (4.11)
21.19 (5.82)
20.14 (7.92)
3.38 (4.02)
2.90 (2.76)
1.11 (0.89)
0.92 (0.73)

Table 4 Means, and Standard Deviations of Scores in BAI, CES-D, ADI (BD, CD, and ED),
and SISE at Baseline and on Day 30 in Overweight/Obese BMI Group.
Assessment
BAI

Group

N

MVM
Placebo

21
23

Baseline Mean* (SD**)
1.24 (0.44)
1.09 (0.29)
30

Day 30 Mean (SD)
1.05 (0.22)
1.04 (0.21)

Table 4 (Cont.)
Assessment

Group

N

MVM
Placebo
MVM
BD
Placebo
MVM
ADI
CD
Placebo
MVM
ED
Placebo
MVM
SISE
Placebo
* Unadjusted means
** SD, Standard deviation

21
23
21
23
21
23
21
23
21
23

CES-D

Baseline Mean* (SD**)
10.48 (4.55)
9.17 (2.62)
7.86 (6.37)
7.09 (4.78)
20.52 (6.05)
20.52 (6.05)
6.48 (5.13)
5.78 (4.39)
1.71 (1.01)
1.39 (0.78)

Day 30 Mean (SD)
9.10 (4.98)
6.48 (3.38)
7.43 (7.49)
4.96 (2.85)
19.61 (6.00)
18.43 (7.35)
4.52 (5.09)
3.00 (2.65)
1.62 (0.92)
1.26 (0.69)

6.3 Effects of MVM Supplementation on Mental Health-Related Outcomes
Shown in Table 5 are the mean and standard deviation of scores of BAI, CES-D, ADI
(BD, CD, and ED), and SISE pre- and post-intervention after controlling for covariates such
as gender, BMI, food security score, as well as caffeine, fruit, and vegetable intakes with
p-values of within- and between-subject comparisons. Within subject results indicated the
effect of supplementation within the placebo-controlled group from baseline to Day 30 or the
effect of supplementation within the MVM supplementation group from baseline to Day 30.
Between subject results indicated the effect of supplementation between the
placebo-controlled group and the MVM supplementation group from baseline to Day 30.
6.31 Effects within MVM Supplementation Group or Placebo-Controlled Group
Box’s test of equality of covariance matrices showed no violation of assumption
(p>0.01). Concerning within-subject results, there was a difference within MVM
supplementation group in depression from baseline to the last day of intervention while
controlling for gender, BMI, food security score, as well as fruits, vegetables, and caffeine
intake. There was also a difference within placebo-controlled group from baseline to Day 30
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in depression. F (1, 90) = 3.43, p= 0.03, partial η2= 0.04. However, there was no difference
within MVM supplementation group or within placebo-controlled group from baseline to Day
30 in terms of anxiety, F(1, 91)= 1.03, p= 0.16, partial η2= 0.11; behavioral dysregulation, F(1,
90)= 2.58, p= 0.06, partial η2= 0.03; cognitive dysregulation, F(1, 90)= 0.02, p= 0.44, partial
η2< 0.01; emotional dysregulation, F(1, 90)= 0.01, p= 0.47, partial η2< 0.01; or self-esteem
level, F(1, 90)= 1.24, p= 0.13, partial η2= 0.01. There was a medium effect size within MVM
supplementation group or within placebo-controlled group in anxiety (partial η 2= 0.11). There
were also small effect sizes in behavioral dysregulation (partial η 2= 0.03) and self-esteem
level (partial η2= 0.01).
6.32 Effects between MVM Supplementation Group and Placebo-Controlled Group
With respect to between-subject results, Levene’s test of equality of error variances
showed no violation of assumption (p> 0.05) except for cognitive dysregulation on Day 30
(FDay 30= 4.23, pDay 30= 0.04). There was a difference between MVM supplementation group
and placebo-controlled group from baseline to Day 30 after controlling for gender, BMI, food
security score and intake of fruits, vegetables, and caffeine in terms of depression, F(1, 90)=
4.11, p= 0.02, partial η2= 0.04. There was no difference for anxiety, F(1, 91)= 0.30, p= 0.29,
partial η2< 0.01; behavioral dysregulation, F(1, 90)= 0.05, p= 0.41, partial η2< 0.01; cognitive
dysregulation, F(1, 90)= 0.02, p= 0.44, partial η2< 0.01; emotional dysregulation, F(1, 90)=
0.07, p= 0.39, partial η2< 0.01; and self-esteem level, F(1, 90)= 2.44, p= 0.06, partial η2= 0.03.
There was a small effect size in self-esteem level (partial η2= 0.03) between MVM
supplementation group and placebo-controlled group.

32

Table 5 Adjusted* Means, Standard Deviation of Scores in BAI, CES-D, ADI (BD, CD, and
ED), and SISE Pre- and Post-Intervention with P Value Showing the Significance within MVM
Supplementation Groups or Placebo-Controlled Group or Between MVM Supplementation
Groups and Placebo-Controlled Group and with Partial η 2 Showing the Effect Size within
MVM Supplementation Groups or Placebo-Controlled Group or Between MVM
Supplementation Groups and Placebo-Controlled Group.

Assessment

Group

N

Baseline
Meanadj
(SD**)

Day 30
Meanadj
(SD)

P w#

Partial
Δ
η2W

§

Pb

Partial
◎
η2b

MVM
53 1.09 (0.30)
1.02 (0.14)
0.16
0.11₤
0.29
<0.01
Placebo 50 1.06 (0.24)
1.02 (0.14)
MVM
53 9.42 (3.86)
7.81 (3.96)
†
†
CES-D
0.03
0.04€
0.02
0.04€
Placebo 49 8.65 (2.95)
6.39 (3.38)
MVM
53 6.60 (5.39)
5.34 (6.00)
BD
0.06
0.03€
0.41
<0.01
Placebo 49 6.82 (4.52)
4.90 (4.11)
MVM
53 21.21 (5.74)
21.19 (5.82)
ADI
CD
0.44
<0.01
0.44
<0.01
Placebo 49 21.10 (5.34)
20.14 (7.92)
MVM
53 5.08 (4.41)
3.38 (4.02)
ED
0.47
<0.01
0.39
<0.01
Placebo 49 5.27 (3.86)
2.90 (2.76)
MVM
53 1.38 (0.95)
1.11 (0.89)
SISE
0.13
0.01€
0.06
0.03€
Placebo 49 1.12 (0.78)
0.92 (0.73)
* Adjusted for gender, BMI, food security score, caffeine intake, and fruit and vegetable
intakes.
** SD, Standard deviation
† P<0.05
# Pw showing the significance within MVM supplementation groups or placebo-controlled
group.
Δ Partial η2W showing the effect size within MVM supplementation groups or
placebo-controlled group.
§Pb showing the significance between MVM supplementation groups and placebo-controlled
group.
◎ Partial η2b showing the effect size between MVM supplementation groups or
placebo-controlled group.
€ Partial η2 showing small effect
₤ Partial η2 showing medium effect
6.4 Effects of MVM Supplementation in Overweight/Obese BMI Group
BAI

Indicated in Table 6 are the means and standard deviations of BAI, CES-D, ADI (BD,
CD, and ED), and SISE pre- and post- intervention in overweight/obese BMI groups after
adjusting for gender, food security score, caffeine intake, and fruit and vegetable intake with
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one-tailed p-values of within- and between-subject. Within subject results indicated the effect
of supplementation in overweight/obese BMI group within the placebo-controlled group from
baseline to Day 30 or the effect of supplementation within the MVM supplementation group
from baseline to Day 30. Between subject results indicated the effect of supplementation in
overweight/obese BMI group between the placebo-controlled group and the MVM
supplementation group from baseline to Day 30.
6.41 Effects within MVM Supplementation Group or Placebo-Controlled Group in
Overweight/Obese BMI Group
With reference to within-subject results, Box’s test of equality of covariance matrices
showed no violation of assumptions (p> 0.01) except for behavioral dysregulation (Box’s M=
20.56, F= 6.50, p< 0.01). There was no difference within MVM supplementation group or
placebo-controlled group from Day 0 to Day 30 in overweight/obese BMI group while
controlling for gender, food security score, as well as fruits, vegetables, and caffeine intake
regarding anxiety, F(1, 34)= 2.52, p= 0.06, partial η2= 0.07; depression, F(1, 34)= 2.68, p=
0.06, partial η2= 0.07; behavioral dysregulation, F(1, 34)= 0.03, p= 0.43, partial η2< 0.01;
cognitive dysregulation, F(1, 34)= 2.61, p= 0.06, partial η2=0.07; emotional dysregulation, F(1,
34)= 0.11, p= 0.37, partial η2< 0.01; or self-esteem level, F(1, 34)= 0.12, p= 0.37, partial η2<
0.01. There were medium effect sizes in anxiety, depression, and cognitive dysregulation
within MVM supplementation or within placebo-controlled group in overweight/obese BMI
group (partial η2= 0.07).
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6.42 Effects between MVM Supplementation Group and Placebo-Controlled Group in
Overweight/Obese BMI Group
With respect to between-subject results, Levene’s test of equality of error variances
showed no violation of assumptions (p> 0.05) except for baseline anxiety, Fbaseline= 5.33,
pbaseline= 0.03, behavioral dysregulation on Day 30, FDay 30= 5.37, pDay 30= 0.03, and cognitive
dysregulation on Day 30, FDay 30= 4.43, pDay 30= 0.04. There was no statistically significant
difference between MVM supplementation group and placebo-controlled group from baseline
to Day 30 in overweight/obese BMI group after controlling for gender, food security score and
intake of fruits, vegetables, and caffeine in terms of anxiety, F(1, 34)= 0.46, p= 0.25, partial
η2= 0.01; depression, F(1, 34)= 2.45, p= 0.06, partial η2= 0.07; behavioral dysregulation, F(1,
34)= 0.70, p= 0.21, partial η2= 0.02; cognitive dysregulation, F(1, 34)= 0.21, p= 0.33, partial
η2= 0.01; emotional dysregulation, F(1, 34)= 0.51, p= 0.24, partial η2= 0.02; or self-esteem
level, F(1, 34)= 1.46, p= 0.12, partial η2= 0.04. There was a medium effect size in depression
between MVM supplementation and placebo-controlled group in overweight/obese BMI
group (partial η2= 0.07). Also, there were small effect sizes in anxiety (partial η 2= 0.01),
behavioral dysregulation (partial η 2= 0.02), cognitive dysregulation (partial η 2= 0.01),
emotional dysregulation (partial η 2= 0.02), and self-esteem level (partial η2= 0.04) between
MVM supplementation and placebo-controlled group in overweight/obese BMI group.

35

Table 6 Adjusted* Means, Standard Deviation of Scores in BAI, CES-D, ADI (BD, CD, and
ED), and SISE Pre- and Post-Intervention in Overweight/Obese BMI Group with P Value
Showing the Significance within MVM Supplementation Groups or Placebo-Controlled Group
or Between MVM Supplementation Groups and Placebo-Controlled Group and with Partial η2
Showing the Effect Size within MVM Supplementation Groups or Placebo-Controlled Group
or Between MVM Supplementation Groups and Placebo-Controlled Group.
Partial
Partial
Baseline
2 Δ
ηW
η2b◎
Day 30
§
#
Assessment Group
N
Meanadj
Pw
Pb
Meanadj (SD)
(SD**)
MVM
21 1.24 (0.44)
1.05 (0.22)
0.07₤
0.01€
0.06
0.25
Placebo 23 1.09 (0.29)
1.04 (0.21)
MVM
21 10.48 (4.55) 9.10 (4.98)
0.07₤
0.07₤
CES-D
0.06
0.06
Placebo 23 9.17 (2.62)
6.48 (3.38)
MVM
21 7.86 (6.37)
7.43 (7.49)
<0.01
0.02€
BD
0.43
0.21
Placebo 23 7.09 (4.78)
4.96 (2.85)
MVM
21 20.52 (6.05) 19.62 (6.00)
0.07₤
0.01€
ADI
CD
0.06
0.33
Placebo 23 19.91 (5.58) 18.43 (7.35)
MVM
21 6.48 (5.13)
4.52 (5.09)
<0.01
0.02€
ED
0.37
0.24
Placebo 23 5.78 (4.39)
3.00 (2.65)
MVM
21 1.71 (1.00)
1.62 (0.92)
<0.01
0.04€
SISE
0.37
0.12
Placebo 23 1.39 (0.78)
1.26 (0.69)
* Adjusted for gender, food security score, caffeine intake, and fruit and vegetable intakes.
** SD, Standard deviation
# Pw showing the significance within MVM supplementation groups or placebo-controlled
group in overweight/obese BMI group.
Δ Partial η2W showing the effect size within MVM supplementation groups or
placebo-controlled group in overweight/obese BMI group.
§Pb showing the significance between MVM supplementation groups and placebo-controlled
group in overweight/obese BMI group.
◎ Partial η2b showing the effect size between MVM supplementation groups or
placebo-controlled group in overweight/obese BMI group.
€ Partial η2 showing small effect
₤ Partial η2 showing medium effect
BAI
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Chapter 4
7 Discussion
7.1 The MVM Supplementation will Decrease Symptoms of Depression in Young
Adults.
In the current study using the MVM supplement in participants aged 18-24 years, few
differences were found in the MVM supplementation group in symptoms of anxiety,
depression, dysregulation, or self-esteem level compared to placebo-controlled group. While
controlling for gender, BMI, food security score, and intake of caffeine, fruits, and vegetables,
there was a difference in score changes in depression within MVM supplementation group or
within placebo-controlled group (p= 0.03). There was also a difference in score changes in
depression between MVM supplementation group and placebo-controlled group (p= 0.02).
Therefore, our MVM supplementation may reduce depressive symptoms in young adults. We
found no difference in the score changes in MVM supplementation group or
placebo-controlled group in anxiety, behavioral dysregulation, cognitive dysregulation,
emotional dysregulation, and self-esteem level (p> 0.05). There was no difference in score
changes between MVM supplementation group and placebo-controlled group in anxiety,
behavioral dysregulation, cognitive dysregulation, emotional dysregulation, and self-esteem
level (p> 0.05) either. However, when looking closer to the effect size, the results showed a
medium effect size within MVM supplementation group or within placebo-controlled group in
anxiety (partial η2= 0.11). The results also showed small effect sizes in behavioral
dysregulation (partial η2= 0.03) and self-esteem level (partial η2= 0.01). Between MVM
supplementation group and placebo-controlled group, the results also showed a small effect
size in self-esteem level (partial η2= 0.03). A small effect size means that where a real effect,
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while a large effect size shows a big enough and consistent enough effect.
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Therefore, our

MVM supplementation tends to lower the rates of anxiety, behavioral dysregulation, and
self-esteem level within the MVM supplementation group or within the placebo-controlled
group and tends to lower the rate of self-esteem level in MVM supplementation group
compared to placebo-controlled group. However, lack of statistical significance may be due to
our small sample size or the way we conducted the analysis.
7.2 The MVM Supplementation Tends to Decrease Symptoms of Anxiety, Depression,
Dysregulation, and Self-Esteem Level in Overweight/Obese BMI Group in Young
Adults.
Studies in young adults specific to examination of psychological impairments such as
anxiety, depression, self-esteem level, dysregulation, and poor body image are sparse.
Therefore, the mechanism by which weight status affects mental health remains unknown. In
our current study, there was no difference in changes of anxiety, depression, behavioral
dysregulation, cognitive dysregulation, emotional dysregulation, or self-esteem level within
MVM supplementation group or within placebo-controlled group from baseline to Day 30 in
overweight/obese BMI group (p> 0.05) with adjustment for gender, food security score, and
intake of caffeine, fruits, and vegetables. There was no difference in MVM supplementation
group in changes of anxiety, depression, behavioral dysregulation, cognitive dysregulation,
emotional dysregulation, or self-esteem level compared to placebo-controlled group (p> 0.05)
either in overweight/obese BMI group. When we looked at effect size, we found medium
effect sizes in anxiety, depression, and cognitive dysregulation within MVM supplementation
or within placebo-controlled group in overweight/obese BMI group (partial η 2= 0.07).
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Compared to placebo-controlled group, there was a medium effect size in depression in MVM
supplementation group in overweight/obese BMI group (partial η 2= 0.07). Also, there were
small effect sizes in anxiety (partial η2= 0.01), behavioral dysregulation (partial η 2= 0.02),
cognitive dysregulation (partial η 2= 0.01), emotional dysregulation (partial η2= 0.02), and
self-esteem level (partial η2= 0.04) in MVM supplementation group in overweight/obese BMI
group in comparison to placebo-controlled group. A small effect size means that where a real
effect, while a large effect size shows a big enough and consistent enough effect.
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Therefore,

our MVM supplementation tends to reduce the rates of anxiety, depression, and cognitive
dysregulation within MVM supplementation group or placebo-controlled group. Also, the
MVM supplementation tends to decrease symptoms of behavioral dysregulation, emotional
dysregulation, and self-esteem level in the supplementation group compared to the
placebo-controlled group. However, lack of statistical significance may be due to our small
sample size or the way we conducted the analysis.
7.3 Comparison with Previous Studies
The lack of effect is in contrast to what Carroll et al. 34 found in a 28-day study, which
was that Berocca® was associated with anxiety reduction. The lack of beneficial effect is also
in contrast to the findings from the 30-day study of Schlebusch et al. 35 that Berocca®
decreased symptoms of anxiety and stress and improved psychological general well-being.
Moreover, lack of effect is also in contrast to the results from other previous studies using
Berocca®. Kennedy et al. 36 suggested that a 33-day supplementation lowered stress and
tiredness and improved alertness and physical health in comparison to placebo-controlled
group. This discrepancy between our study and previous studies may be due to various
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participants’ characteristics. Carroll et al. 34 recruited male participants aged 18-42 years.
Participants in the study by Schlebusch et al.

35

were 18-65 years of age, even if they had an

age subgroup of 18-44 year olds. Male participants aged 30-55 years were in the study of
Kennedy et al. 36 Thus, the age range of participants in these studies of 18-65 years old was
broad whereas our study was more focused and investigated emerging adults aged 18-24
years. Varying sample sizes may also contribute to the discrepancy from our findings to
previous work. The sample sizes in the studies of Schlebusch et al.

35

and Kennedy et al. 36

were more than 200. Another possibility for the difference in outcomes is the difference in
instruments used to assess mental health. The questionnaires in the previous studies used to
detect participants’ physical and mental health were the General Health Questionnaire (GHQ),
Hospital Anxiety and Depression Scale (HADS), Profile of Mood States (POMS), Visual
Analogue Mood Scales (VAS), and State-Trait Anxiety Inventory (STAI). We in our current
study used Beck Anxiety Inventory (BAI), Center for Epidemiologic Studies Depression Scale
(CES-D), Abbreviated Dysregulation Inventory (ADI), and a single item for self-esteem level
(SISE). A final possible explanation for no effect observed in our study is a potential placebo
effect, where participants in the placebo group had improvement simply because they
thought they were taking the active supplement.
Lewis et al. 41 used a B-complex supplement for 60 days. They also used BAI and
Beck Depression Inventory (BDI) as an assessment to determine anxiety level. They found
beneficial effects of decreased symptoms of anxiety and depression. 41 This may indicate that
B vitamins contribute to our mental health. However, their participants were depressive adults,
not healthy adults as in our study. The similar result was found in the 28-day study of White et
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al. 37, which was that Berocca® supplementation decreased depressive symptoms. This may
also show the role of vitamins and minerals in our brain biochemistry to decrease depressive
symptoms and improve mental health in healthy people.
Our findings also seemed close to what Pipingas et al.
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found, which was that MVM

supplementation had few positive effects on mood. However, there were differences in our
methodologies. The length of their study was 16 weeks, which was 4 times longer than ours.
Also, the supplement they used contained botanicals such as Korean ginseng, Ginkgo Biloba,
Chamomile, and green tea; evidence suggests that botanicals may have beneficial effects on
mood. Moreover, men and women were given different supplements with slightly different
doses of vitamins and minerals. Lastly, the age range of their participants was 20-50 years
old rather than our participants of 18-24 years old. Therefore, the dissimilarity in length of the
intervention, in supplement content, and in participants’ characteristics may influence the
effect of MVM supplementation on mental health.
7.3 Strengths/Limitations and Future Directions
Our first strength is that we focused specifically on young adults aged 18-24 years
who are at a distinct developmental stage. 3 As they graduate from high school and
experience various changes in love, work, and worldviews, it is likely that new environment
influences their characteristics, behaviors, and mental health. 3 Also, depression is the most
common problem in American college students, 6 which may develop suicide. Therefore, we
paid particular attention to this population. Also, weight status may influence one’s
self-esteem level and then influence his/her mental health. Thus, we adjusted BMI as a
covariate and investigated the effect of our supplementation on mental health in young adults

41

in overweight/obese BMI group. Another strength of our study is that the supplement we used
contained only vitamins and minerals while some supplements other studies used contained
botanical ingredients or caffeine, which may itself influence our mood or may influence the
effect of the supplementation on mood. Finally, we recorded participants’ caffeine, fruit, and
vegetable intake via ASA 24-h dietary recall and adjusted the intake in analysis for controlling
the confounding effect from caffeine, fruits, and vegetables that participants had. This is also
a strength. However, the study has limitations. We did not ask participants’ race in our current
study. However, different races and cultures may have various mental health-related
outcomes. Also, the compliance might be influenced since participants self-reported if they
took the supplement. It is likely that they forgot to take the supplement but still reported that
they took it. Thus, objective biological assessments such as blood or urine sample may
provide a better way to check the compliance and a more comprehensive testing
methodology. Moreover, some of the results showed good effect sizes instead of statistical
significance. This may be because our sample size was relatively small. The insufficient
sample size may result in type II error which gives us false negative results. Therefore, further
studies may consider the method with a combination of biological tests and self-report
questionnaires. Also, race should be a characteristic that will be asked in future studies.
Lastly, future studies with a larger sample size are in warranted.
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Chapter 5
8 Conclusion
There was a significant difference in score changes of depression within MVM
supplementation group or within placebo-controlled group from baseline to Day 30. Also, a
difference was found between MVM supplementation group and placebo-controlled group
from baseline to Day 30 in depression. Therefore, our MVM supplementation may have
beneficial effects in depression in young adults. It may also improve young adults’ quality of
life in terms of depression. There was no difference in score changes of anxiety,
dysregulation, or self-esteem level within MVM supplementation group or within
placebo-controlled group from baseline to Day 30. There was no difference in anxiety,
depression, dysregulation, or self-esteem level in overweight/obese BMI group from baseline
to Day 30. However, our MVM supplementation tends to have beneficial effects in anxiety,
depression, dysregulation, and self-esteem level according to moderate effect sizes. Future
studies are warranted to clarify the conflicting results and should take into consideration
improvements in study design such as a question about race, objective biological
assessment, and a larger sample size.
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